Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic launched the Extended infusion set in the U.S., the first infusion set allowing up to 7-day wear for insulin pumps, reducing insulin waste and plastic usage. This innovation leads to annual cost savings of up to 25% on insulin and a 50% reduction in plastic waste. The extended wear time decreases the frequency of set changes by 50% and enhances comfort, addressing patient needs. The set is available for MiniMed 600 and 700 series pump users, aiming to ease diabetes management.
Ra Medical Systems (RMED) reported financial results for Q3 2022, highlighting a merger plan with Catheter Precision. This stock-for-stock reverse-merger aims to tap into the growing cardiac electrophysiology market. Company CEO Will McGuire cited $13.7 million in cash and an additional $7.4 million raised through their At-the-Market facility. They aim to meet NYSE listing requirements post-reverse stock split, with expectations to finalize the merger by early 2023. Catheter’s FDA-cleared product, VIVO™, targets ventricular arrhythmias, a significant unmet need in cardiac care.
Cloud DX (CDXFF) has partnered with Medtronic (MDT) and other organizations to develop a Continuous Connected Patient Care (CCPC) platform aimed at enhancing home care for discharged patients. The project, with a total investment of $12.8 million and $5.2 million in funding from the Digital Supercluster, is set to launch in 2024. The initiative includes a new vital sign monitoring device and aims to alleviate hospital capacity issues by allowing remote patient monitoring, particularly for those with chronic conditions.
On November 7, 2022, Medtronic (NYSE:MDT) presented six-month results from the SPYRAL HTN-ON MED clinical trial at the AHA Scientific Sessions 2022. The trial showed a significant reduction in office-based systolic blood pressure (OSBP) for patients treated with the Symplicity Spyral RDN System, but the primary endpoint of ambulatory systolic blood pressure (ABPM) reduction was not statistically significant. The company's PMA package has been submitted to the FDA for review. The study met its primary safety endpoint, demonstrating a low incidence of adverse events.
Medtronic has launched the Neurovascular Co-Lab™ Platform to enhance collaboration among start-ups, physicians, and institutions for stroke care innovation. This initiative aims to expedite the development of advanced technologies to benefit stroke patients globally. The platform will be operational by World Stroke Day, October 29, 2022, and is designed to facilitate the submission and funding of high-potential neurovascular innovations. Medtronic highlights the urgent need for improved stroke treatments, noting that millions remain untreated despite the availability of therapies.
Medtronic plc (NYSE:MDT) will participate in the CECP's 10th CEO Investor Forum at AdvaMed's 2022 MedTech Conference on October 25, 2022, in Boston, MA. CEO Geoff Martha will present at 3:30 p.m. CDT and answer questions.
A live webcast will be available on the same day via the Investor Events link on Medtronic's investor relations page, with a replay accessible within 24-48 hours.
Medtronic is a global leader in healthcare technology, dedicated to alleviating pain and restoring health through innovative solutions.
Medtronic plc (NYSE:MDT) has announced plans to separate its Patient Monitoring and Respiratory Interventions businesses into a new entity, referred to as NewCo. This strategic move aims to enhance operational focus and drive value creation for stakeholders. The separation is expected to be tax-free for U.S. shareholders and is anticipated to complete within 12 to 18 months, subject to regulatory approvals. NewCo will provide connected care solutions, leveraging its strong commercial footprint and wide-ranging product portfolio, which generated approximately $2.2 billion in revenue in fiscal 2022.
Medtronic (NYSE:MDT) announced significant approvals for its Hugo™ robotic-assisted surgery system, enhancing its market presence globally. The approvals include CE Mark clearance for general surgery in the EU, a license for laparoscopic surgery in Canada, and MHLW approval for urologic and gynecologic laparoscopic procedures in Japan. These milestones position Medtronic to access key markets, particularly in Japan, the third-largest robotic surgery market, and capitalize on the growth of minimally invasive procedures, which account for over 80% of global RAS procedures.
Medtronic plc has launched a groundbreaking program called My Insights for users of the MiniMed™ 770G system, utilizing data science to deliver personalized diabetes management tips and trends. This is the first program offering tailored insights based on individual user data, enhancing diabetes care with monthly educational emails. The MiniMed 770G system, known for its automated insulin adjustments and smartphone connectivity, supports users aged two and above. Medtronic aims to simplify diabetes management and empower users with customized tools.
Medtronic has received FDA approval for its SelectSecure Model 3830 cardiac lead to include left bundle branch area pacing, enhancing its conduction system pacing capabilities for patients with bradycardia. This innovative method mimics natural heart contraction, reducing complications associated with traditional pacing. The approval is based on evidence from over 20,000 patients, demonstrating a 92% procedural success rate and a low complication rate of 2.5%. Medtronic remains the only company with FDA-approved therapies for conduction system pacing, further solidifying its leading position in cardiac pacing technologies.
FAQ
What is the current stock price of Medtronic (MDT)?
What is the market cap of Medtronic (MDT)?
